{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:16:31Z","timestamp":1778634991421,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","award":["GUP-2021-004"],"award-info":[{"award-number":["GUP-2021-004"]}],"id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004768","name":"Kolej Universiti Teknikal Kebangsaan Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004768","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.xphs.2024.05.010","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T06:58:26Z","timestamp":1715842706000},"page":"2044-2054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Next-generation Dengue Vaccines: Leveraging Peptide-Based Immunogens and Advanced Nanoparticles as Delivery Platforms"],"prefix":"10.1016","volume":"113","author":[{"given":"Nur Adilah Abdul","family":"Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah Al-Hadi Ahmad","family":"Fuaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nor Azila Muhammad","family":"Azami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-1328","authenticated-orcid":false,"given":"Mohd Cairul Iqbal Mohd","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazren","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.xphs.2024.05.010_bib0001","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1371\/journal.pntd.0000890","article-title":"Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards","volume":"4","author":"Beatty","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"10.1016\/j.xphs.2024.05.010_bib0002","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2024.05.010_bib0003","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/1381612823666170913163904","article-title":"Development of peptide vaccines in dengue","volume":"24","author":"Reginald","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.xphs.2024.05.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6803098","article-title":"Dengue fever: causes, complications, and vaccine strategies","volume":"2016","author":"Khetarpal","year":"2016","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.xphs.2024.05.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003749","article-title":"The complexity of a dengue vaccine: a review of the human antibody response","volume":"9","author":"Flipse","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.xphs.2024.05.010_bib0006","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1371\/journal.pntd.0001180","article-title":"Age-specificity of clinical dengue during primary and secondary infections","volume":"5","author":"Thai","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.xphs.2024.05.010_bib0007","series-title":"Dengue Virus, in Emerging and Reemerging Viral Pathogens","first-page":"281","author":"Murugesan","year":"2020"},{"issue":"7","key":"10.1016\/j.xphs.2024.05.010_bib0008","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.010_bib0009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2024.05.010_bib0010","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent developments in recombinant protein\u2013based dengue vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2024.05.010_bib0011","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s12038-009-0114-3","article-title":"Nanovaccines: recent developments in vaccination","volume":"34","author":"Nandedkar","year":"2009","journal-title":"J Biosci"},{"key":"10.1016\/j.xphs.2024.05.010_bib0012","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"21","key":"10.1016\/j.xphs.2024.05.010_bib0013","doi-asserted-by":"crossref","first-page":"15319","DOI":"10.1074\/jbc.R700009200","article-title":"Toll-like receptors and Type I interferons","volume":"282","author":"Uematsu","year":"2007","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.xphs.2024.05.010_bib0014","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.vaccine.2009.12.046","article-title":"Structure\u2013activity relationship of lipopeptide Group A Streptococcus (GAS) vaccine candidates on toll-like receptor 2","volume":"28","author":"Zaman","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.010_bib0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"John","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"10.1016\/j.xphs.2024.05.010_bib0016","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1073\/pnas.1105079108","article-title":"Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance","volume":"108","author":"John","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.xphs.2024.05.010_bib0017","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","article-title":"A protective role for dengue virus-specific CD8+ T cells","volume":"182","author":"Yauch","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.010_bib0018","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"St John","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1574-695X.2007.00273.x","article-title":"Denguevirus-specific suppressor T cells: current perspectives","volume":"50","author":"Chaturvedi","year":"2007","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2024.05.010_bib0020","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/324320","article-title":"Strong HLA class I\u2013restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?","volume":"184","author":"Loke","year":"2001","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.xphs.2024.05.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008676","article-title":"Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccine","volume":"14","author":"Ahmed","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"405","key":"10.1016\/j.xphs.2024.05.010_bib0022","doi-asserted-by":"crossref","first-page":"eaal5088","DOI":"10.1126\/scitranslmed.aal5088","article-title":"Increased adaptive immune responses and proper feedback regulation protect against clinical dengue","volume":"9","author":"Simon-Loriere","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.010_bib0023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1201-9712(02)90073-1","article-title":"Long-term memory cellular immune response to dengue virus after a natural primary infection","volume":"6","author":"Sierra","year":"2002","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.xphs.2024.05.010_bib0024","unstructured":"Guglani, L. and S. Kabra, T cell immunopathogenesis of dengue virus infection. 2005."},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/vaccines7030058","article-title":"Recent advances in the development of peptide vaccines and their delivery systems against Group A Streptococcus","volume":"7","author":"Azuar","year":"2019","journal-title":"Vaccines"},{"issue":"5979","key":"10.1016\/j.xphs.2024.05.010_bib0026","first-page":"328","article-title":"Enhancing cross-reactive anti-prM dominates the human antibody response in dengue infection","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.xphs.2024.05.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100071","article-title":"Commercial manufacturing of current good manufacturing practice peptides spanning the gamut from neoantigen to commercial large-scale products","volume":"9","author":"Pennington","year":"2021","journal-title":"Med Drug Discov"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.010_bib0028","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"key":"10.1016\/j.xphs.2024.05.010_bib0029","unstructured":"Emergex receives regulatory approval for a phase I clinical trial in dengue of a T-cell priming vaccine. 2021 [cited 2023; Available from: https:\/\/emergexvaccines.com\/emergex-receives-regulatory-approval-for-a-phase-i-clinical-trial-in-dengue-of-a-t-cell-priming-vaccine\/."},{"key":"10.1016\/j.xphs.2024.05.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104922","article-title":"Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study","volume":"99","author":"Miauton","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-09199-w","article-title":"Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection","volume":"7","author":"Ali","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2024.05.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2020.100430","article-title":"Delineating blueprint of an epitope-based peptide vaccine against the multiple serovars of dengue virus: a hierarchical reverse vaccinology approach","volume":"20","author":"Islam","year":"2020","journal-title":"Inform Med Unlocked"},{"issue":"8","key":"10.1016\/j.xphs.2024.05.010_bib0033","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/acsptsci.2c00130","article-title":"Immunoinformatics-aided design and in vivo validation of a peptide-based multiepitope vaccine targeting canine circovirus","volume":"5","author":"Kaushik","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.xphs.2024.05.010_bib0034","unstructured":"Oluwaseun, F.A., N.R.S. Sibuyi, and R. Darius, Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus. 2021."},{"key":"10.1016\/j.xphs.2024.05.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104728","article-title":"Immunoinformatics designed T cell multi epitope dengue peptide vaccine derived from non structural proteome","volume":"150","author":"Krishnan","year":"2021","journal-title":"Microb Pathog"},{"issue":"21","key":"10.1016\/j.xphs.2024.05.010_bib0036","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1021\/acs.orglett.0c03279","article-title":"Peptide modification via N-terminal-residue-directed \u03b3-C (sp3)\u2013H arylation","volume":"22","author":"Hou","year":"2020","journal-title":"Org Lett"},{"key":"10.1016\/j.xphs.2024.05.010_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.583272","article-title":"Applications of thiol-ene chemistry for peptide science","volume":"8","author":"Nolan","year":"2020","journal-title":"Front Chem"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0038","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/MMBR.00028-16","article-title":"Lipoproteins of Gram-positive bacteria: key players in the immune response and virulence","volume":"80","author":"Nguyen","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0039","doi-asserted-by":"crossref","first-page":"30648","DOI":"10.1038\/srep30648","article-title":"Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2024.05.010_bib0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fimmu.2013.00318","article-title":"Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships","volume":"4","author":"Zaman","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2024.05.010_bib0041","doi-asserted-by":"crossref","unstructured":"Kowalczyk, R., P.W. Harris, G.M. Williams, S.-H. Yang, and M.A. Brimble, Peptide lipidation\u2013a synthetic strategy to afford peptide based therapeutics. Peptides and peptide-based biomaterials and their biomedical applications, 2017: p. 185\u2013227.","DOI":"10.1007\/978-3-319-66095-0_9"},{"key":"10.1016\/j.xphs.2024.05.010_bib0042","series-title":"Peptide Lipidation\u2013A Synthetic Strategy to Afford Peptide Based Therapeutics, in Peptides and Peptide-based Biomaterials and Their Biomedical Applications","first-page":"185","author":"Kowalczyk","year":"2017"},{"issue":"7","key":"10.1016\/j.xphs.2024.05.010_bib0043","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.4049\/jimmunol.151.7.3728","article-title":"Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis","volume":"151","author":"Zhong","year":"1993","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/j.xphs.2024.05.010_bib0044","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1016\/j.bmc.2014.09.042","article-title":"Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant","volume":"22","author":"Azmi","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.1016\/j.xphs.2024.05.010_bib0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/vaccines9050499","article-title":"Cell-penetrating peptides-based liposomal delivery system enhanced immunogenicity of peptide-based vaccine against Group A Streptococcus","volume":"9","author":"Yang","year":"2021","journal-title":"Vaccines"},{"issue":"24","key":"10.1016\/j.xphs.2024.05.010_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115823","article-title":"A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: lipidation and polyelectrolyte complexes","volume":"28","author":"Zhao","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"15","key":"10.1016\/j.xphs.2024.05.010_bib0047","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1021\/jm300822g","article-title":"Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based toll-like receptor 2 ligand","volume":"55","author":"Abdel-Aal","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2024.05.010_bib0048","series-title":"Peptide Applications in biomedicine, Biotechnology and Bioengineering","author":"Koutsopoulos","year":"2017"},{"key":"10.1016\/j.xphs.2024.05.010_bib0049","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1385\/IR:35:3:233","article-title":"Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease","volume":"35","author":"Batzloff","year":"2006","journal-title":"Immunol Res"},{"issue":"27","key":"10.1016\/j.xphs.2024.05.010_bib0050","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1016\/j.biomaterials.2012.05.041","article-title":"Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope","volume":"33","author":"Rudra","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.xphs.2024.05.010_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121614","article-title":"Structure-activity relationship of lipid, cyclic peptide and antigen rearrangement of physically mixed vaccines","volume":"617","author":"Huang","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.05.010_bib0052","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jconrel.2022.09.038","article-title":"Mannose in vaccine delivery","volume":"351","author":"Nahar","year":"2022","journal-title":"J Control Release"},{"issue":"9","key":"10.1016\/j.xphs.2024.05.010_bib0053","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/intimm\/10.9.1299","article-title":"Strongly increased efficiency of altered peptide ligands by mannosylation","volume":"10","author":"Agnes","year":"1998","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0054","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/intimm\/dxm123","article-title":"Immunization with mannosylated peptide induces poor T cell effector functions despite enhanced antigen presentation","volume":"20","author":"Kel","year":"2008","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/acschembio.9b00987","article-title":"C-Mannosyl lysine for solid phase assembly of mannosylated peptide conjugate cancer vaccines","volume":"15","author":"Hogervorst","year":"2020","journal-title":"ACS Chem Biol"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-59711-y","article-title":"Preclinical development of a fusion peptide conjugate as an HIV vaccine immunogen","volume":"10","author":"Ou","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0057","first-page":"173","article-title":"An improved protocol for coupling synthetic peptides to carrier proteins for antibody production using DMF to solubilize peptides","volume":"18","author":"Lateef","year":"2007","journal-title":"J Biomol Tech: JBT"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0058","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0059","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acsabm.1c01238","article-title":"Peptides for vaccine development","volume":"5","author":"Hamley","year":"2022","journal-title":"ACS Appl Bio Mater"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.010_bib0060","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4+ T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.xphs.2024.05.010_bib0061","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1128\/jvi.69.10.6077-6089.1995","article-title":"Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction","volume":"69","author":"Lairmore","year":"1995","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0062","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1080\/22221751.2022.2140608","article-title":"A novel RBD-protein\/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.xphs.2024.05.010_bib0063","first-page":"1","article-title":"Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein","author":"Sirohi","year":"2020","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.010_bib0064","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/vaccines8030417","article-title":"Enhancement of tetravalent immune responses to highly conserved epitopes of a dengue peptide vaccine conjugated to polystyrene nanoparticles","volume":"8","author":"Chan","year":"2020","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.010_bib0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/cmi.2017.92","article-title":"Multi-epitope vaccines: a promising strategy against tumors and viral infections","volume":"15","author":"Zhang","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"15","key":"10.1016\/j.xphs.2024.05.010_bib0066","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1073\/pnas.85.15.5409","article-title":"Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system","volume":"85","author":"Tam","year":"1988","journal-title":"Proc Natl Acad Sci"},{"issue":"17\u201318","key":"10.1016\/j.xphs.2024.05.010_bib0067","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.vaccine.2005.01.041","article-title":"Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides","volume":"23","author":"Olive","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0068","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1021\/jm701091d","article-title":"Structure\u2013activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates","volume":"51","author":"Abdel-Aal","year":"2008","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.xphs.2024.05.010_bib0069","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/cmdc.201500227","article-title":"Lipopeptide nanoparticles: development of vaccines against hookworm parasite","volume":"10","author":"Fuaad","year":"2015","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.xphs.2024.05.010_bib0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.xphs.2024.05.010_bib0071","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2017.09.001","article-title":"Targeting dendritic cells through gold nanoparticles: a review on the cellular uptake and subsequent immunological properties","volume":"91","author":"Ahmad","year":"2017","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0072","doi-asserted-by":"crossref","first-page":"34215","DOI":"10.1038\/srep34215","article-title":"A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates","volume":"6","author":"Swaminathan","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.xphs.2024.05.010_bib0073","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.bioconjchem.8b00090","article-title":"Optimization of surface display of DENV2 E protein on a nanoparticle to induce virus specific neutralizing antibody responses","volume":"29","author":"Coffman","year":"2018","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.xphs.2024.05.010_bib0074","article-title":"A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2024.05.010_bib0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.actbio.2018.08.011","article-title":"Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus","volume":"78","author":"Quach","year":"2018","journal-title":"Acta Biomater"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.010_bib0076","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/infdis\/jir814","article-title":"Conserved MHC class I\u2013presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response","volume":"205","author":"Testa","year":"2012","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.xphs.2024.05.010_bib0077","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1080\/21645515.2017.1369639","article-title":"A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles","volume":"13","author":"Huang","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0078","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0022-1759(92)90275-X","article-title":"T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides","volume":"155","author":"Widmann","year":"1992","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.010_bib0079","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4049\/jimmunol.152.2.549","article-title":"Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs","volume":"152","author":"Shirai","year":"1994","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1099\/0022-1317-80-1-187","article-title":"Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus","volume":"80","author":"Hiranuma","year":"1999","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.010_bib0081","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/vaccines3040875","article-title":"A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes","volume":"3","author":"Xiang","year":"2015","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.010_bib0082","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/pharmaceutics14010156","article-title":"DENV-Mimetic polymersome nanoparticles bearing multi-epitope lipopeptides antigen as the next-generation dengue vaccine","volume":"14","author":"Abdul Rahman","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.05.010_bib0083","first-page":"86","article-title":"Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: a randomized, double-blind, placebo-controlled Phase 1 trial","author":"Friedman-Klabanoff","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.010_bib0084","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2012.01.030","article-title":"Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses","volume":"159","author":"Fernando","year":"2012","journal-title":"J Control Release"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:51:04Z","timestamp":1724741464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0022354924001849"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.05.010","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation Dengue Vaccines: Leveraging Peptide-Based Immunogens and Advanced Nanoparticles as Delivery Platforms","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}